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CORRESPONDENCE
Safety and Histological Effect of Liquid Nitrogen
Metered Spray Cryotherapy in the Lung
To the Editor:
Chronic bronchitis is characterized by inﬂammation, cough, and
increased mucus production. There is no cure, and current
treatment options are limited to addressing symptoms (1). The
RejuvenAir System (CSA Medical, Inc., Lexington, MA) is a device
designed to bronchoscopically address chronic bronchitis by
delivering liquid nitrogen (LN2) as a metered cryospray (MCS).
MCS is controlled by a thermocouple on the delivery catheter that
feeds back real-time information regarding the amount of LN2
being delivered. That amount is tailored such that each bronchial airway
receives a standardized amount of LN2 based on airway size, leading to a
10-mm circular cryoablation with a depth between 0.1 and 0.5 mm.
On the basis of older generations of LN2 spray interventions
(2, 3), it is hypothesized that LN2 can induce an airway tissue
healing effect by destroying the hyperplastic goblet cells and excess
submucous glands. The extracellular matrix facilitates rapid
regrowth of normal epithelium without scarring, a hallmark of
cryoablation (4, 5). The healing resulting from LN2 MCS is the
basis of this proposed treatment.
To start this project, we evaluated the safety of delivering LN2 in
two small pilot studies. Two sprays were delivered into the lobar and
ﬁrst segmental bronchi, which would be the most distal extent of the
anticipated airway treatment in chronic bronchitis, based on the
signiﬁcant goblet cell pathology present in these areas (6). The primary
endpoint for each study was the evaluation of device-related serious
adverse events (SAEs). The initial study (NCT02106143, previously
reported as an American Thoracic Society 2016 conference abstract
[7]) was conducted in subjects who were scheduled to undergo
lobectomy or pneumonectomy immediately after MCS. The second
study (NCT02483052) evaluated the same device-related SAEs as the
initial study, plus postprocedure safety, as these subjects had a planned
lobectomy after MCS. Both studies had evaluation of potential
histologic effects of MCS as a secondary endpoint, and the specimens
were reviewed by an independent pathologist skilled in cryothermic
tissue injuries (J.C.). Procedures were performed by ﬂexible
bronchoscopy under general anesthesia, using an endotracheal tube
with positive pressure ventilation. During the LN2 spray, the
endotracheal tube was disconnected from the ventilator with the cuff
deﬂated, both to allow N2 gas egress. Major inclusion criteria included
FEV1 >50% of predicted, no bullae .3 cm, and no previous lung
surgery of any sort. Both studies were approved by the local ethics
committees, and all patients provided informed consent.
Overall, 16 subjects were enrolled and treated at three sites
in Europe and Canada. The initial study enrolled 11 (three
women/eight men) subjects, with a mean (6SD) age of 65.86 8.9
years (range, 45.7–74.8 years), a mean FEV1% predicted of 86.16
28.1% (range, 46–132%), and a smoking history of 28.36 20.5
pack-years (range, 0.02–54.0 pack-years). Mean time to the
scheduled surgical resection after MCS was 37.76 21.8 minutes
(range, 15–80 minutes). In the delayed study, ﬁve subjects (four
women/one man) were enrolled, with a mean age of 66.86 6.2
years (range, 59.2–74.0 years), a mean FEV1% predicted of 72.86
16.5% (range, 51–91%), and a smoking history of 29.86 22.4 pack-
years (range, 4.5–47.0 pack-years). Mean time to resection
after MCS was 146 1.4 days (range, 12–16 days). Final
histopathological diagnosis was non–small-cell lung cancer in 15
patients, and small-cell lung cancer in 1 patient.
All intended 32 LN2 MCS were given. The delivery of MCS was
both feasible and safe, with no device-related (S)AEs. There were
no intraoperative complications with stable vital signs, and no
technical difﬁculties preventing application of MCS. Three SAEs
were reported in each study, all determined to be unrelated to the
study device, the MCS treatment, or bronchoscopy, as adjudicated
by an independent medical monitor. The SAEs all occurred after
completion of MCS and video-assisted thoracoscopic surgery
(VATS): atrial ﬁbrillation (8 days after), mucus plug (3 days after),
and death more than 30 days after LN2 spray resulting from
hospital-acquired pneumonia after pneumonectomy in the
nontreated lung; one subject had intraoperative bleeding during
VATS (14 days after MCS), an immediate postoperative bleeding,
and bleeding again 18 days after VATS.
Eight immediate resection subjects’ treated bronchial segments
were available, with ﬁve of them revealing the presence of the
intended cryothermic histologic changes. In the regions with
greater epithelial changes, minimal to mild acute inﬂammation was
present. In two specimens, there was extension into the submucosa,
with cryothermic changes involving the submucosal glands with
preservation of the underlying submucosal structure, including no
effect on the underlying cartilage (Figure 1).
Figure 1. Representative 2-hour post–liquid nitrogen metered
cryospray–treated bronchial micrograph demonstrating surface and
superficial ductal epithelial removal to a depth up to 500 m (hematoxylin
and eosin stained, 4003 magnification). The submucosal extracellular
matrix remains intact (nondenatured) with mild capillary congestion and
minimal luminal-oriented acute inflammation and edema.
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In the delayed resection study, a bronchoscopy was performed just
before lung resection took place. The video of these bronchoscopies was
independently reviewed by an experienced bronchoscopist (R.B.), with
three subjects showing a slight mucosal whitening, one of which seemed
to represent subtle white rings consistent with cryoablation. Airway
caliber was normal, and there were no signs of infection. All ﬁve subjects
had bronchial segments submitted for histopathological evaluation.
Because of the lack of visual mucosal changes after ﬁxation, identiﬁcation
of the treatment sites represented a major limitation in the subsequent
histologic evaluation. Histology ﬁndings were consistent with complete
re-epithelialization at the treatment site. No persistent treatment-related
epithelial erosions, acute inﬂammation, granulomatous inﬂammation,
mucosal necrosis, ﬁbroproliferative healing, or collagenous luminal
narrowing were identiﬁed (see Figure 2 for a representative example).
The bronchial cartilage rings primarily appeared unremarkable, with
one specimen showing focal cartilage ring necrosis, consistent with
possible cryothermic injury or nonspeciﬁc degenerative changes.
In summary, the data obtained in both clinical trials met the
primary and secondary endpoints, with safe delivery of MCS to the
segmental and/or lobar bronchi without device-related SAEs.
Histology from immediate resection specimens documented MCS
effect and nonscarring healed tissue from the delayed resection group.
The information learned from this study is important for the
future development of a bronchoscopic treatment for patients who
suffer from chronic bronchitis. Although this future intended
indication was not speciﬁcally studied in these patients, they share some
chronic bronchitis characteristics, such as exposure to cigarettes and
most having chronic obstructive pulmonary disease. Using MCS in a
similar population and determining the immediate and delayed healing
response has provided important information in the stepwise clinical
development of the system. These results warrant further investigation
in a larger clinical trial targeting patients with chronic bronchitis, which
is currently underway (NCT02483637). n
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Figure 2. Representative 14-day post–liquid nitrogen metered
cryospray–treated bronchial micrograph demonstrating complete rejuvenative
healing, characterized by pseudostratified respiratory epithelium with occasional
goblet cells, preservation of the submucosa and cartilage, and absence of
inflammation and fibrosis (hematoxylin and eosin stained, 4003 magnification).
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